Do the

D 2007

Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?

ZAORALOVÁ, Romana, Henrieta GREŠLIKOVÁ, Hana FILKOVÁ, Pavel NĚMEC, Petr KUGLÍK et. al.

Basic information

Original name

Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?

Name in Czech

Kompentzují "nové léky" vliv negativních cytogenetických prognostických markerů u mnohočetného myelomu?

Authors

ZAORALOVÁ, Romana (203 Czech Republic), Henrieta GREŠLIKOVÁ (703 Slovakia), Hana FILKOVÁ (203 Czech Republic), Pavel NĚMEC (203 Czech Republic), Petr KUGLÍK (203 Czech Republic, guarantor), Alexandra OLTOVÁ (203 Czech Republic), Luděk POUR (203 Czech Republic), Zdeněk ADAM (203 Czech Republic), Jana SMEJKALOVÁ (203 Czech Republic), Andrea KŘIVANOVÁ (203 Czech Republic), Marta KREJČÍ (203 Czech Republic) and Roman HÁJEK (203 Czech Republic)

Edition

Volume 21, Supplement 1. Edinburgh, Blood reviews, p. 131-131, 2007

Publisher

Churchill Livingstone

Other information

Language

English

Type of outcome

Stať ve sborníku

Field of Study

Genetics and molecular biology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.922

RIV identification code

RIV/00216224:14110/07:00022791

Organization unit

Faculty of Medicine

ISSN

UT WoS

000249533100219

Keywords in English

multiple myeloma; cIg FISH; velcade; thalidomide

Abstract

ORIG CZ

V originále

Background In our study, we have concentrated on four aberrations in multiple myeloma (MM) malignant plasma cells: deletions of tumor suppressor genes RB (locus 13q14) and p53 (17q13), translocation involving IGH gene t(4;14), and actually focused amplification of CKS1B gene in 1q21 locus. All of these aberrations are known as negative prognostic factors in patients (pts) treated by conventional therapy or stem cell transplantation. Aims The aim of this study is to show if these selected aberrations act as negative prognostic factors also in patients treated by Velcade or by thalidomide, new drugs used in relapsed patients. Methods We have an increasing group of (recently 42) MM patients. Overall clinical characteristics of the patients at the start of treatment: Average age 63.7 years (SD = 9.4), 57 % (24) of men. 12 % (5/42 pts) were in stage IA, 26 % (11/42 pts) were in stage IIA, 60 % (25/42 pts) were in stage IIIA and 2 % (1 patient) was in stage IIIB. 69 % (29/42 pts) were in first relapse, 24 % (10/42 pts) were in second relapse and the other 7 % (3/42 pts) were in third relapse. 85 % (36/42) pts received at least four cycles of therapy. 64 % (27/42) pts reached overall response (OR) during the follow up (average follow up was 11.0 months, SD = 5.3 months). For identification of malignant plasma cells in bone marrow samples, we use cytoplasmic immunoglobulin (cIg) labeling methodology (Ahmann et al. 1998). This method allows us to identify simultaneously monotypic plasma cells by monoclonal antibody fluorescence (anti-kappa or anti-lambda) and to detect chromosomal abnormalities by FISH (cIg-FISH). Results Cytogenetic findings: Deletion of RB gene was found in 57 % (21/37) of successfully examined patients, deletion of p53 gene was in 53 % (17/32) pts, translocation t(4;14) was in 61 % (22/36) pts and amplification of 1q21 was in 65 % (22/34) pts. Statistical comparison of clinical response in patients with or without each aberration: We have found no significant difference when compared overall survival (OS), time to progression (TTP), progression free survival (PFS), duration of response (DOR) and overall response in subgroups of patients with and without of any selected aberration. Summary/Conclusions In our group of patients, no one of monitored aberrations seems to have any impact, neither positive nor negative, on efficiency of used treatment. It is possible that new drugs, Velcade and thalidomide, antagonize the impact of cytogenetic negative prognostic factors in relapsed patients with MM. However, we will continue in this research to reach larger data set to confirm or disconfirm our results. If this data will be confirmed on larger group of patients, it looks necessary to find other chromosomal abnormalities, relevant for prediction of the prognosis in these patients.

In Czech

Předběžné výsledky, které naznačují, že nové léky možná kompenzují vliv klasických cytogentických negativních prognostických markerů u mnohočetného myelomu.

Links

LC06027, research and development project

Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)

Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group

Citovat

ZAORALOVÁ, Romana, Henrieta GREŠLIKOVÁ, Hana FILKOVÁ, Pavel NĚMEC, Petr KUGLÍK, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Jana SMEJKALOVÁ, Andrea KŘIVANOVÁ, Marta KREJČÍ and Roman HÁJEK. Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma? In Blood reviews. Volume 21, Supplement 1. Edinburgh: Churchill Livingstone, 2007, p. 131. ISSN 0268-960X.

@inproceedings{726947,
   author = {Zaoralová, Romana and Grešliková, Henrieta and Filková, Hana and Němec, Pavel and Kuglík, Petr and Oltová, Alexandra and Pour, Luděk and Adam, Zdeněk and Smejkalová, Jana and Křivanová, Andrea and Krejčí, Marta and Hájek, Roman},
   address = {Edinburgh},
   booktitle = {Blood reviews},
   edition = {Volume 21, Supplement 1},
   keywords = {multiple myeloma; cIg FISH; velcade; thalidomide},
   language = {eng},
   location = {Edinburgh},
   pages = {131-131},
   publisher = {Churchill Livingstone},
   title = {Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?},
   year = {2007}
}

TY  - JOUR
ID  - 726947
AU  - Zaoralová, Romana - Grešliková, Henrieta - Filková, Hana - Němec, Pavel - Kuglík, Petr - Oltová, Alexandra - Pour, Luděk - Adam, Zdeněk - Smejkalová, Jana - Křivanová, Andrea - Krejčí, Marta - Hájek, Roman
PY  - 2007
TI  - Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?
PB  - Churchill Livingstone
CY  - Edinburgh
KW  - multiple myeloma
KW  - cIg FISH
KW  - velcade
KW  - thalidomide
N2  - Background In our study, we have concentrated on four aberrations in multiple myeloma (MM) malignant plasma cells: deletions of tumor suppressor genes RB (locus 13q14) and p53 (17q13), translocation involving IGH gene t(4;14), and actually focused amplification of CKS1B gene in 1q21 locus. All of these aberrations are known as negative prognostic factors in patients (pts) treated by conventional therapy or stem cell transplantation. Aims The aim of this study is to show if these selected aberrations act as negative prognostic factors also in patients treated by Velcade or by thalidomide, new drugs used in relapsed patients. Methods We have an increasing group of (recently 42) MM patients. Overall clinical characteristics of the patients at the start of treatment: Average age 63.7 years (SD = 9.4), 57 % (24) of men. 12 % (5/42 pts) were in stage IA, 26 % (11/42 pts) were in stage IIA, 60 % (25/42 pts) were in stage IIIA and 2 % (1 patient) was in stage IIIB. 69 % (29/42 pts) were in first relapse, 24 % (10/42 pts) were in second relapse and the other 7 % (3/42 pts) were in third relapse. 85 % (36/42) pts received at least four cycles of therapy. 64 % (27/42) pts reached overall response (OR) during the follow up (average follow up was 11.0 months, SD = 5.3 months). For identification of malignant plasma cells in bone marrow samples, we use cytoplasmic immunoglobulin (cIg) labeling methodology (Ahmann et al. 1998). This method allows us to identify simultaneously monotypic plasma cells by monoclonal antibody fluorescence (anti-kappa or anti-lambda) and to detect chromosomal abnormalities by FISH (cIg-FISH). Results Cytogenetic findings: Deletion of RB gene was found in 57 % (21/37) of successfully examined patients, deletion of p53 gene was in 53 % (17/32) pts, translocation t(4;14) was in 61 % (22/36) pts and amplification of 1q21 was in 65 % (22/34) pts. Statistical comparison of clinical response in patients with or without each aberration: We have found no significant difference when compared overall survival (OS), time to progression (TTP), progression free survival (PFS), duration of response (DOR) and overall response in subgroups of patients with and without of any selected aberration. Summary/Conclusions In our group of patients, no one of monitored aberrations seems to have any impact, neither positive nor negative, on efficiency of used treatment. It is possible that new drugs, Velcade and thalidomide, antagonize the impact of cytogenetic negative prognostic factors in relapsed patients with MM. However, we will continue in this research to reach larger data set to confirm or disconfirm our results. If this data will be confirmed on larger group of patients, it looks necessary to find other chromosomal abnormalities, relevant for prediction of the prognosis in these patients.
ER  -

ZAORALOVÁ, Romana, Henrieta GREŠLIKOVÁ, Hana FILKOVÁ, Pavel NĚMEC, Petr KUGLÍK, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Jana SMEJKALOVÁ, Andrea KŘIVANOVÁ, Marta KREJČÍ and Roman HÁJEK. Do the ''new drugs'' antagonize the impact of unfavourable cytogenetic markers in multiple myeloma? In \textit{Blood reviews}. Volume 21, Supplement 1. Edinburgh: Churchill Livingstone, 2007, p.~131. ISSN~0268-960X.

Detailed Information on Publication Record

Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?

Basic information

Original name

Name in Czech

Authors

Edition

Publisher

Other information

Language

Type of outcome

Field of Study

Country of publisher

Confidentiality degree

Impact factor

RIV identification code

Organization unit

ISSN

UT WoS

Keywords in English

Tags

Tags

Abstract

V originále

In Czech

Links